March 25, 2015 / 11:29 AM / 3 years ago

BUZZ-Oncolytics Biotech Inc: Gets orphan status for cancer drug in Europe

** Canadian cancer drug developer’s U.S.-listed shares up 14 pct at $0.90 premarket

** The European Medicines Agency grants orphan drug designation to company’s lead drug, Reolysin, to treat patients with ovarian cancer

** The status gives the drug developer a number of incentives, including 10-year marketing exclusivity in Europe

** The U.S. Food and Drug Administration granted Reolysin orphan status for ovarian and fallopian tube cancer earlier this month

** The drug is also being tested for other cancer indications, including breast, pancreatic and head or neck cancer

** Up to Tuesday’s close, stock had risen nearly 50 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below